: iStockAnalyst.com Symbols Feed

Isis Pharmaceuticals (Nasdaq: ISIS) Breaches Longterm Support

Mon, 05 Oct 2009 16:47:00 GMT

I highlighted Isis Pharmaceuticals a few weeks ago believing that a sell-off causing a price decline from $19 to $16/share was a prime opportunity to buy a potential high-growth business. It seems, however, that my proclamation may not have been entirely correct. And, post last week’s trading, I’ve liquidated my position in ISIS.[More...]

Safe(r) Ways To Play Biotech

Tue, 18 Aug 2009 13:52:00 GMT

I recently highlighted a small biotech firm, ISIS Pharmaceuticals, as a potential “value” growth play. ISIS took a tumble after earnings despite being just a penny off of estimates. Despite slightly lower than expected earnings, the Company showed a strong cash position, moderate cash burn, and a likelihood that it would be able to at least make it through full trials for its most promising drug. I know that for some even this doesn’t count as value. Afterall, the Company is not free cash positive and any value ascribed to the Company is derived from future expectations of its drug pipeline of which there are none currently in distribution. For those looking for more proven business models but still looking to take advantage of the coming shift towards genetic pharmaceuticals as[More...]

ISIS Pharmaceuticals (NasdaqGM: ISIS) Makes Antisense

Tue, 11 Aug 2009 13:14:03 GMT

Since bottoming near the end of 2008, ISIS Pharmaceuticals has been one of the hottest stocks in the first half of 2009. In fact, in just a few short months, the stock has exhibited all the tell tale signs of a powerful, interim trend reversal. More importantly, a look at ISIS’s 3-year weekly chart shows that despite a dramatic correction in 2008, the stock[More...]

FDA Calendar Updates: Orexo, Novo Nordisk, King, Isis, Facet

Mon, 10 Aug 2009 13:56:00 GMT

Below is a summary of updates to the BioMedReports.com FDA Calendar, which includes a database of 294 entries as of 8/6/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of BioMedReports.com, the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, ANDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete (...)[More...]

Genzyme (NASDAQ:GENZ): Robust Growth Prospects At Clearance Sale Prices

Fri, 07 Aug 2009 16:55:10 GMT

In late July, Genzyme (NASDAQ:GENZ) reported 2Q09 results, including revenue of $1.23 billion (up 5% from $1.17 billion during 2Q08 and up 11% excluding unfavorable currency exchange rates). The Company's Non-GAAP net income (which excludes stock compensation and certain business acquisition items) rose to $232.5 million or $0.85 per diluted share versus $107 million or $0.38 per diluted share in the year-ago period. During 2Q09, Genzyme generated about $281 million in cash (primarily derived fr (...)[More...]

Pharmaceuticals & Biotech - Industry Outlook

Tue, 09 Jun 2009 12:05:35 GMT

The pharmaceutical industry is entering a period of substantial change in 2009. Most of the names in the industry are facing significant patent challenges in the years to come. U.S.-based firms are facing foreign exchange headwinds, as well. Revenue growth is non-existent, and earnings growth is being driven primarily by mergers, cost-cutting and share buybacks. Knowing that investors rarely pay-up for this type of manufactured earnings growth, we struggle to see a broad-based out-performance for the large-cap pharmaceutical sector in 2009. Valuations, however, are attractive, with several of the largest players trading at PEs below 10x, including: Pfizer (PFE, 7.5x), Eli Lilly (LLY,[More...]

FDA, Clinical Trial Updates: Heart Stents, Cholesterol In The News

Thu, 21 May 2009 12:24:12 GMT

Below is a summary of updates to the BioMedReports.com database of over 200 entries included in the FDA and Clinical Trial Calendars. The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA decision deadline dates while the Clinical Trial Calendar encompasses pending clinical trial results (with a focus on late-stage, Phase 3 trials), pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, s (...)[More...]

FDA, Clinical Trial Calendar Updates: WYE, SVNT, AMRN, ISIS, SLXP, SOMX

Fri, 08 May 2009 15:51:00 GMT

FDA, Clinical Trial Calendar Updates: Genzyme, Isis, Osiris, Roche, Watson

Wed, 22 Apr 2009 16:03:43 GMT

ISIS: Big Blockbuster Potential

Mon, 06 Apr 2009 19:38:00 GMT

Highlights include Isis Pharmaceutical, Inc. (ISIS) and Genzyme Corp. (GENZ). We are keeping our Buy rating and $22 price target on Isis Pharmaceuticals (ISIS). We encourage investors to pick up the shares at this level. We think commercialization of mipomersen for HoFH under an accelerated approval should come in early 2011. Mipomersen represents one of the largest potential blockbuster drugs to come to market in the next few years. Additionally, the path to market outside the U.S. may be easier than the Street anticipates.[More...]

OncoGenex Reports Second Quarter 2009 Financial Results

Thu, 06 Aug 2009 20:49:00 GMT

Conference Call on Thursday, August 6, 2009 at 4:30 p.m. Eastern Time
BOTHELL, WA, and VANCOUVER, Aug. 6 /CNW/ - OncoGenex Pharmaceuticals, Inc. ("OncoGenex" or the "Company") (NASDAQ: OGXI) today reported unaudited financial results for the second quarter and six months ended June 30, 2009 and reviewed the Company's highlights for the second quarter of 2009.
The following consolidated results reflect the operations of OncoGenex Technologies Inc. ("OncoGenex Technologies") prior to the August 21, 2008 reverse takeover of Sonus Pharmaceuticals, Inc. ("Sonus"), and the consolidated results of OncoGenex thereafter.

: iStockAnalyst.com Symbols Feed

Isis Pharmaceuticals (Nasdaq: ISIS) Breaches Longterm Support

Safe(r) Ways To Play Biotech

ISIS Pharmaceuticals (NasdaqGM: ISIS) Makes Antisense

FDA Calendar Updates: Orexo, Novo Nordisk, King, Isis, Facet

Genzyme (NASDAQ:GENZ): Robust Growth Prospects At Clearance Sale Prices

Pharmaceuticals & Biotech - Industry Outlook

FDA, Clinical Trial Updates: Heart Stents, Cholesterol In The News

FDA, Clinical Trial Calendar Updates: WYE, SVNT, AMRN, ISIS, SLXP, SOMX

FDA, Clinical Trial Calendar Updates: Genzyme, Isis, Osiris, Roche, Watson

ISIS: Big Blockbuster Potential

OncoGenex Reports Second Quarter 2009 Financial Results

OncoGenex Pharmaceuticals to Raise $9.5 Million Through Sale of Common Stock

Isis Acquires Common Shares and Warrants of iCo Therapeutics

Analyst Actions: Anadigics, Isis Pharmaceuticals, The Knot

Genzyme Reports Third-Quarter Financial Results

Alnylam and Regulus Receive Notice of Allowance from United States Patent and Trademark Office for New Patent Covering microRNA Therapeutics

OncoGenex Pharmaceuticals Announces Issuance of Key Patent for OGX- 011

Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009

Isis Pharmaceuticals to Present at Canaccord Adams' 29th Annual Global Growth Conference

OncoGenex Pharmaceuticals Completes $9.5 Million Registered Direct Offering

Webcast Alert: Isis Pharmaceuticals' Second Quarter 2009 Financial Results Conference Call

Genzyme Delivers Solid Second-Quarter Financial Results

InvestorSoup.com Issues Trading Outlook for Genta Inc.

BenchmarkJournal.Com Free Analyst Review for THQI, CTCM, JOSB, ISIS, CETV and BEAT

Form 4 BENNETT C FRANK For: Jul 23 (10K)

Form 4 PARSHALL B LYNNE For: Jul 06 (10K)

Form 4 WENDER JOSEPH H For: Jul 01 (10K)

Form 4 Geary Richard S For: Jul 01 (10K)

Form 4 BENNETT C FRANK For: Apr 22 (10K)

Form 4 BENNETT C FRANK For: Apr 07 (10K)

Form 4 PARSHALL B LYNNE For: Jan 05 (10K)

Form 4 PARSHALL B LYNNE For: Dec 30 (10K)

Form 4 Geary Richard S For: Jan 01 (10K)

Form 4 BENNETT C FRANK For: Jan 01 (10K)